RT Journal Article
T1 In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.
A1 Hernandez-Garcia, Marta
A1 Garcia-Castillo, Maria
A1 Ruiz-Garbajosa, Patricia
A1 Bou, German
A1 Siller-Ruiz, Maria
A1 Pitart, Cristina
A1 Gracia-Ahufinger, Irene
A1 Mulet, Xavier
A1 Pascual, Alvaro
A1 Tormo, Nuria
A1 Canton, Rafael
K1 Carbapenemase-producing Enterobacterales
K1 Carbapenemase-producing Pseudomonas aeruginosa
K1 Cefepime-taniborbactam susceptibility
AB Novel β-lactam-β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime-VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales (n = 247) and carbapenem-resistant Pseudomonas species (n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MICFTB, ≤8/4 mg/L) and Pseudomonas (67.1% MICFTB, ≤8/4 mg/L) populations. The MICFTB was >8 mg/L in 6/247 (2.4%) Enterobacterales isolates (3 KPC-producing Klebsiella pneumoniae isolates, 1 VIM-producing Enterobacter cloacae isolate, 1 IMP-producing E. cloacae isolate, and 1 NDM-producing Escherichia coli isolate) and in 56/170 (32.9%) Pseudomonas isolates, 19 of them carbapenemase producers (15 producers of VIM, 2 of GES, 1 of GES+VIM, and 1 of GES+KPC). Against the Enterobacterales isolates with meropenem MICs of >2 mg/L (138/247), FTB was the most active agent against both serine-β-lactamases (107/138) and MBL producers (31/138) (97.2 and 93.5% MICFTB, ≤8/4 mg/L, respectively), whereas the activity of comparators was reduced, particularly against the MBL producers (ceftazidime-avibactam, 94.4 and 12.9%, meropenem-vaborbactam, 85.0 and 64.5%, imipenem-relebactam, 76.6 and 9.7%, ceftolozane-tazobactam, 1.9 and 0%, and piperacillin-tazobactam, 0 and 0%, respectively). Among the meropenem-resistant Pseudomonas isolates (163/170; MIC, >2 mg/L), the activities of FTB against serine-β-lactamase (35/163) and MBL (43/163) producers were 88.6 and 65.1%, respectively, whereas the susceptibilities of comparators were as follows: ceftazidime-avibactam, 88.5 and 16.0%, meropenem-vaborbactam, 8.5 and 7.0%, imipenem-relebactam, 2.9 and 2.3%, ceftolozane-tazobactam, 0 and 2.3%, and piperacillin-tazobactam, 0 and 0%, respectively. Microbiological results suggest FTB as a potential therapeutic option in patients infected with carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas isolates, including MBL producers.
PB American Society for Microbiology
YR 2022
FD 2022-01-03
LK http://hdl.handle.net/10668/20034
UL http://hdl.handle.net/10668/20034
LA en
NO Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, et al. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0216121
NO This project was sponsored by Venatorx Pharmaceuticals and has been funded in wholeor in part with federal funds from the Department of Health and Human Services, Office ofthe Assistant Secretary for Preparedness and Response, Biomedical Advanced Research andDevelopment Authority, under contract no. HHSO100201900007C. This study was alsosupported by Plan Nacional de I1D 1 i 2013–2016 and Instituto de Salud Carlos III,Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio deEconomía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases(RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008,RD16/0016/0010, and REIPI RD16/0016/0011), cofinanced by the European DevelopmentRegional Fund “A Way to Achieve Europe” (ERDF), operative program Intelligent Growth2014–2020 and CIBER en Enfermedades Infecciosas (CIBERINF) (CB21/13/00084).
DS RISalud
RD Apr 12, 2025